Impaired cognition and attention in adults: pharmacological management strategies

Hervé Allain¹, Yvette Akwa², Lucette Lacomblez³, Alain Lieury⁴, Danièle Bentué-Ferrer¹

¹Laboratoire de Pharmacologie Expérimentale et Clinique, Pôle des Neurosciences de Rennes, Faculté de Médecine, Université de Rennes I, France; ²INSERM U788, Le Kremlin Bicêtre cedex, France; ³Service de Pharmacologie, Fédération de Neurologie, Hôpital Pitié-Salpêtrière, Paris, France; ⁴Laboratoire de Psychologie Expérimentale, Université de Haute Bretagne, France

Abstract: Cognitive psychology has provided clinicians with specific tools for analyzing the processes of cognition (memory, language) and executive functions (attention-concentration, abstract reasoning, planning). Neuropsychology, coupled with the neurosciences (including neuroimaging techniques), has authenticated the existence of early disorders affecting the “superior or intellectual” functions of the human brain. The prevalence of cognitive and attention disorders is high in adults because all the diseases implicating the central nervous system are associated with cognitive correlates of variable intensity depending on the disease process and the age of the patient. In some pathologies, cognitive impairment can be a leading symptom such as in schizophrenia, posttraumatic stress disorder or an emblematic stigmata as in dementia including Alzheimer’s disease. Paradoxically, public health authorities have only recognized as medications for improving cognitive symptoms those with proven efficacy in the symptomatic treatment of patients with Alzheimer’s disease; the other cognitive impairments are relegated to the orphanage of syndromes and symptoms dispossessed of medication. The purpose of this review is to promote a true “pharmacology of cognition” based on the recent knowledge in neurosciences. Data from adult human beings, mainly concerning memory, language, and attention processes, will be reported. “Drug therapeutic strategies” for improving cognition (except for memory function) are currently rather scarce, but promising perspectives for a new neurobiological approach to cognitive pharmacology will be highlighted.

Keywords: cognitive disorders, attention, memory, pharmacology, treatment, pharmacovigilance, dementia.